Lafayette Investments, Inc. Lineage Cell Therapeutics, Inc. Transaction History
Lafayette Investments, Inc.
- $482 Million
- Q2 2025
A detailed history of Lafayette Investments, Inc. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Lafayette Investments, Inc. holds 13,000 shares of LCTX stock, worth $22,490. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,000
Previous 13,000
-0.0%
Holding current value
$22,490
Previous $5,000
120.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding LCTX
# of Institutions
141Shares Held
106MCall Options Held
368KPut Options Held
0-
Broadwood Capital Inc New York, NY49.6MShares$85.7 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$16.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$14.7 Million0.0% of portfolio
-
Defender Capital, Llc.6.79MShares$11.7 Million2.42% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$9.33 Million6.02% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $294M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...